Intelligent Bio Solutions Inc. (INBS)
USD 1.36
(0.74%)
USD 1.36
(0.74%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | 81.32 Thousand USD | -100.0% |
| 2023 | 759.02 Thousand USD | 0.0% |
| 2022 | - USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 459.67 Thousand USD | -22.12% |
| 2024 Q3 | 150.42 Thousand USD | -67.28% |
| 2024 FY | 81.32 Thousand USD | -89.29% |
| 2024 Q4 | 81.32 Thousand USD | -100.0% |
| 2024 Q1 | 590.26 Thousand USD | -22.23% |
| 2023 FY | 759.02 Thousand USD | 0.0% |
| 2023 Q1 | - USD | 0.0% |
| 2023 Q4 | 759.02 Thousand USD | -35.73% |
| 2023 Q3 | 1.18 Million USD | -14.94% |
| 2023 Q2 | 1.38 Million USD | 0.0% |
| 2022 Q4 | - USD | 0.0% |
| 2022 FY | - USD | 0.0% |
| 2022 Q3 | - USD | 0.0% |
| 2022 Q1 | - USD | 0.0% |
| 2022 Q2 | - USD | 0.0% |
| 2021 Q4 | - USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 3.07 Million USD | 97.354% |
| Biodesix, Inc. | 35.22 Million USD | 99.769% |
| bioAffinity Technologies, Inc. | 1.11 Million USD | 92.729% |
| Castle Biosciences, Inc. | 14.19 Million USD | 99.427% |
| DarioHealth Corp. | 24.59 Million USD | 99.669% |
| Exact Sciences Corporation | 2.47 Billion USD | 99.997% |
| IDEXX Laboratories, Inc. | 622.88 Million USD | 99.987% |
| Illumina, Inc. | 1.48 Billion USD | 99.995% |
| iSpecimen Inc. | 29.13 Thousand USD | -179.176% |
| Standard BioTools Inc. | 3.98 Million USD | 97.958% |
| 23andMe Holding Co. | 67.84 Million USD | 99.88% |
| Medpace Holdings, Inc. | 142.12 Million USD | 99.943% |
| NeoGenomics, Inc. | 606.06 Million USD | 99.987% |
| Inotiv, Inc. | 399.4 Million USD | 99.98% |
| Psychemedics Corporation | 945 Thousand USD | 91.394% |
| Prenetics Global Limited | 867.21 Thousand USD | 90.622% |
| Precipio, Inc. | 106 Thousand USD | 23.279% |
| RadNet, Inc. | 812.06 Million USD | 99.99% |
| Sotera Health Company | 2.22 Billion USD | 99.996% |
| Star Equity Holdings, Inc. | 1.14 Million USD | 92.897% |
| Exagen Inc. | 19.23 Million USD | 99.577% |
| Natera, Inc. | 282.94 Million USD | 99.971% |
| Aspira Women's Health Inc. | 1.43 Million USD | 94.313% |
| Neogen Corporation | 888.39 Million USD | 99.991% |
| Myriad Genetics, Inc. | 130.9 Million USD | 99.938% |
| ICON Public Limited Company | 3.66 Billion USD | 99.998% |
| Bionano Genomics, Inc. | 7.17 Million USD | 98.867% |
| CareDx, Inc | 28.27 Million USD | 99.712% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Twist Bioscience Corporation | 79.17 Million USD | 99.897% |
| Guardant Health, Inc. | 1.13 Billion USD | 99.993% |
| BioNexus Gene Lab Corp. | 98.76 Thousand USD | 17.657% |
| Fulgent Genetics, Inc. | 10.11 Million USD | 99.196% |
| Sera Prognostics, Inc. | 840 Thousand USD | 90.319% |
| OPKO Health, Inc. | 222.03 Million USD | 99.963% |
| Personalis, Inc. | 1.23 Million USD | 93.41% |
| Applied DNA Sciences, Inc. | 739.16 Thousand USD | 88.998% |
| Star Equity Holdings, Inc. | 1.14 Million USD | 92.897% |
| MDxHealth SA | 35.56 Million USD | 99.771% |
| Prenetics Global Limited | 867.21 Thousand USD | 90.622% |
| ENDRA Life Sciences Inc. | 192.06 Thousand USD | 57.657% |
| Mainz Biomed B.V. | 2.19 Million USD | 96.297% |
| Trinity Biotech plc | 54.65 Million USD | 99.851% |
| Neuronetics, Inc. | 59.28 Million USD | 99.863% |
| bioAffinity Technologies, Inc. | 1.11 Million USD | 92.729% |